2025 年套细胞淋巴瘤科学联盟及淋巴瘤研究基金会主办研讨会报告

Mantle cell lymphoma (MCL) is a rare, aggressive form of non-Hodgkin lymphoma that arises from cells within the mantle zone (the outer ring of lymphocytes surrounding the center of a lymphatic nodule). Recent treatment advances, such as the introduction of Bruton tyrosine kinase inhibitors and chimeric antigen receptor T-cell therapies, have improved outcomes for many patients.

Development of resistance is common, though, and relapse rates are high in MCL. The molecular mechanisms that contribute to resistance remain unclear, and the clinical heterogeneity of MCL can make it difficult to predict how patients will respond to treatment.

Thus, there remains an urgent need for continued research on the molecular drivers of MCL pathogenesis, mechanisms of resistance, and novel strategies for targeting these pathways to improve outcomes for patients across the spectrum of disease. In April 2025, researchers gathered for the Lymphoma Research Foundation's 21st Mantle Cell Lymphoma Scientific Consortium and Workshop to discuss recent developments in the characterization and treatment of MCL.

This report, which includes a summary of each presentation, aims to review the findings presented at the workshop and highlight new opportunities and unanswered questions in the care of patients with MCL, paving the way for novel treatments to improve outcomes and experiences in the years to come.